Cutaneous cryptococcosis in a patient taking fingolimod for multiple sclerosis: Here come the opportunistic infections?

Adam F. Carpenter, Shikha J. Goodwin, Peter F. Bornstein, Andrew J. Larson, Christine K. Markus

Research output: Contribution to journalArticlepeer-review

11 Scopus citations

Abstract

Background: Fingolimod is an oral disease-modifying therapy for relapsing forms of multiple sclerosis, which acts by sequestering lymphocytes within lymph nodes. Objective: To describe a case of extrapulmonary cryptococcosis in a patient taking fingolimod. Methods: Case report. Results: A 47-year-old man developed a non-healing skin lesion approximately 16 months after starting treatment with fingolimod. Biopsy revealed cryptococcosis. Fingolimod was discontinued and the lesion resolved with antifungal therapy. Conclusion: Despite few reported opportunistic infections in the pivotal clinical trials and first few years post-marketing, there has been a recent increase in reported AIDS-defining illnesses in patients taking fingolimod. Neurologists should be alert for opportunistic infections in their patients using this medication.

Original languageEnglish (US)
Pages (from-to)297-299
Number of pages3
JournalMultiple Sclerosis
Volume23
Issue number2
DOIs
StatePublished - Feb 1 2017

Keywords

  • AIDS
  • Cryptococcosis
  • cutaneous
  • fingolimod
  • multiple sclerosis
  • skin

PubMed: MeSH publication types

  • Case Reports
  • Journal Article

Fingerprint

Dive into the research topics of 'Cutaneous cryptococcosis in a patient taking fingolimod for multiple sclerosis: Here come the opportunistic infections?'. Together they form a unique fingerprint.

Cite this